Evidence map›Paper›PMID 33960691›Full record

ArticleCancer medicine2021

Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker.

Atsushi Hiraoka, Masaya Kato, Kaori Marui, Taisei Murakami, Kei Onishi, Tomoko Adachi, Junko Matsuoka, Hidetaro Ueki, Takeaki Yoshino, Miho Tsuruta and 12 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Atsushi HiraokaGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.ORCID 0000-0003-1989-0480
Masaya KatoGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Kaori MaruiGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Taisei MurakamiGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Kei OnishiGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Tomoko AdachiGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Junko MatsuokaGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Hidetaro UekiGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Takeaki YoshinoGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Miho TsurutaGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Toshihiko AibikiGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Tomonari OkudairaGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Taira KurodaGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Ryuichiro IwasakiGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Yoshifumi SugaGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Hideki MiyataGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Tomoyuki NinomiyaGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Masashi HirookaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Masanori AbeDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Bunzo MatsuuraDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Kojiro MichitakaGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Yoichi HiasaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Ehime Prefectural Central Hospital · JPEhime University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimLow branched-chain amino acid (BCAA) to tyrosine ratio (BTR) is known as an indicator of amino acid imbalance. We elucidated usefulness of newly developed albumin-bilirubin (ALBI) score as alternative methods of BTR in patients with naïve hepatocellular carcinoma (HCC) retrospectively. MATERIALS/

methodsIn 842 patients with HCC and without BCAA supplementation (71 years, male 614, Child-Pugh A:B:C = 689:116:37), relationships among BTR and clinical features were evaluated. Of those, 438 patients, with Milan criteria HCC, treated curatively were divided into the high-BTR (>4.4) (n = 293) and low-BTR (≤4.4) (n = 145) groups. The prognostic value of BTR was evaluated using inverse probability weighting (IPW) with propensity score.

resultsThe low-BTR group showed worse prognosis than the other (3-, 5-, 10-year overall survival rates: 88.9% vs. 86.3%/70.5% vs. 78.1%/38.1% vs. 52.3%, respectively; p < 0.001). Multivariate Cox-hazard analysis adjusted for IPW showed elderly (≥65 years) HR 2.314, p = 0.001), female gender (HR 0.422, p < 0.001), ECOG PS ≥2 (HR 3.032, p = 0.002), low platelet count (HR 1.757, p = 0.010), and low BTR (≤4.4) (HR 1.852, p = 0.005) to be significant prognostic factors. Both serum albumin level (r = 0.370, p < 0.001) and ALBI score (r = -0.389, p < 0.001) showed a significant relationship with BTR. Child-Pugh class B, modified ALBI grade (mALBI) 2a, and mALBI 2b predictive values for BTR were 3.589, 4.509, and 4.155 (AUC range: 0.735-0.770), respectively, while the predictive value of ALBI score for low-BTR (≤4.4) was -2.588 (AUC 0.790).

conclusionALBI score -2.588 was a predictor for low-BTR (≤4.4), which was prognostic factors for early HCC patients, and at least patients with mALBI 2b might have an amino acid imbalance.

Indexed as

AgedAmino Acids, Branched-ChainBilirubinBiomarkersCarcinoma, HepatocellularChronic DiseaseEpidemiologic MethodsFemaleHumansLiver DiseasesLiver NeoplasmsMaleNutritional StatusPrognosisProtein-Energy MalnutritionSerum AlbuminAmino Acids, Branched-ChainBilirubinBiomarkersSerum AlbuminTyrosinealbumin-bilirubin scoreamino acid imbalancebranched-chain amino acid to tyrosine ratiohepatocellular carcinomamodified ALBI gradenutrition

Identifiers

PMID33960691
PMCPMC8178498
OpenAlexW3159503429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.